BioSpace News Archive

Keeping in mind the development of the healthcare sector across both developed as well as developing countries, the global oscillating positive expiratory pressure devices market is expected to witness a steady growth in the coming years of the forecast period.

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that the last participant has completed the planned 24 weeks in the Phase II PEGASUS trial assessing the safety and biological activity of AMX0035 admini

Potential Vaccine Candidate Employs Novel Exosome-Based mRNA Delivery Platform that Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins Capricor Scheduling Pre-IND Meeting with FDA to Discuss Clinical Strategy

Dr. Reddy’s Laboratories Ltd. announced a preclinical data presentation for E7777, its engineered IL-2-diphtheria toxin fusion protein, at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting, being held virtually.

Travecta Therapeutics, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier, announces today the appointment of Jerold Chun, M.D, Ph.D. to its scientific advisory board.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 3rd International Conference on Sanfilippo syndrome and related diseases sponsored by the Fondation Sanfilippo Suisse (Sanfilippo Foundation Switzerland).

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up.

Quality data a top priority for improving digital engagement with HCPs as 88% of sales reps now use digital channels to reach providers

Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced the successful closing of an oversubscribed US$200 million crossover financing round.

Genialis, a leader in applied data science for the development of precision medicines, will present a poster alongside OncXerna (fka Oncologie) at the upcoming Society for Immunotherapy of Cancer conference (SITC 2020)